Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Bristol-Myers Squibb CoTrade
iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs iShares Core S&P 500 ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.92 (market cap $129.94B), while iShares Core S&P 500 ETF trades at $776.78. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals.

BMYIVV
Market Cap
$129.94B
Sector
HealthBroad Market / Factor
52-Week High
$65.89$776.81
52-Week Low
$42.60$634.93
Enterprise Value
$163.92B
Dividend Yield
3.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.77, up 0.01% with a bullish technical signal from moving averages but overbought RSI readings. The ETF benefits from strong institutional interest, as First Bank & Trust increased its stake by 24.8% in Q2 2026 (SEC filing, August 11, 2026), while Financial Advisory Corp reduced holdings by 3.1%. Market sentiment is mixed amid record highs and inflation concerns, with JPMorgan raising its S&P 500 target to 8,000 (FXEmpire, August 10, 2026).

Outlook remains positive due to robust corporate earnings and AI-driven growth, but risks include high valuations and potential pullbacks. Investors should focus on long-term diversification benefits, with the dividend offering steady income. Key resistance is at $777, with support at $772.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV